Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients

Biomedicine and Pharmacotherapy

Volumn 60, Issue 9, 2006, Pages 508-519

  Brand, Walter ^a,b   Schutte, Maaike E ^b,c   Williamson, Gary ^a   van Zanden, Jelmer J ^b   Cnubben, Nicole H P ^c   Groten, John P ^b,c   van Bladeren, Peter J ^a,b   Rietjens, Ivonne M C M ^b  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c TNO   (Netherlands)

Author keywords

ATP binding cassette (ABC) transport proteins; Flavonoids; Intestinal transcellular transport

Indexed keywords

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, MULTIPLE; FLAVONOIDS; HUMANS; INTESTINES;

EID: 33750353446     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.07.081     Document Type: Article

References (151)

1. Day A.J., Gee J.M., DuPont M.S., Johnson I.T., and Williamson G. Absorption of quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. Biochem. Pharmacol. 65 (2003) 1199-1206
2. Hollman P.C.H., De Vries J.H.M., Van Leeuwen S.D., Mengelers M.J.B., and Katan M.B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr. 62 (1995) 1276-1282
3. Wolffram S., Blöck M., and Ader P. Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush border membrane of rat small intestine. J. Nutr. 132 (2002) 630-635
4. Chan L.M.S., Lowes S., and Hirst B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21 (2004) 25-51
5. Taipalensuu J., Törnblom H., Lindberg G., Einarsson C., Sjöqvist F., Melhus H., et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299 (2001) 164-170
6. Takano M., Yumoto R., and Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 109 (2006) 137-161
7. Zimmermann C., Gutmann H., Hruz P., Gutzwiller J.-P., Beglinger C., and Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. 33 (2005) 219-224
8. Dietrich C.G., Geier A., and Oude Elferink R.P.J. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52 (2003) 1788-1795
9. Hirohashi T., Suzuki H., Chu X.-Y., Tamai I., Tsuji A., and Sugiyama Y. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J. Pharmacol. Exp. Ther. 292 (2000) 265-270
10. Prime-Chapman H.M., Fearn R.A., Cooper A.E., Moore V., and Hirst B.H. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J. Pharmacol. Exp. Ther. 311 (2004) 476-484
11. Scheffer G.L., Kool M., de Haas M., de Vree J.M.L., Pijnenborg A.C.L.M., Bosman D.K., et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 82 (2002) 193-201
12. Lee K., Klein-Szanto A.J., and Kruh G.D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92 (2000) 1934-1940
13. Van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., and Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13 (2002) 595-603
14. Kool M., Van der Linden M., De Haas M., Baas F., and Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 59 (1999) 175-182
15. Madon J., Hagenbuch B., Landmann L., Meier P.J., and Stieger B. Transport function and hepatocellular localization of mrp6 in rat liver. Mol. Pharmacol. 57 (2000) 634-641
16. Beck K., Hayashi K., Dang K., Hayashi M., and Boyd C.D. Analysis of ABCC6 (MRP6) in normal human tissues. Histochem. Cell Biol. 123 (2005) 517-528
17. Bera T.K., Iavarone C., Kumar V., Lee S., Lee B., and Pastan I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl. Acad. Sci. USA 99 (2002) 6997-7002
18. Bortfeld M., Rius M., Konig J., Herold-Mende C., Nies A.T., and Keppler D. Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience 137 (2006) 1247-1257
19. Chen Z.S., Hopper-Borge E., Belinsky M.G., Shchaveleva I., Kotova E., and Kruh G.D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 63 (2003) 351-358
20. Feron V.J., Groten J.P., Hermus R.J.J., Jonker D., Meijerman I., Mulder G.J., et al. Designing experiments for food-drug synergy: safety aspects. In: Thompson L.U., and Ward W.E. (Eds). Food-drug synergy and safety (2006), CRC Press, Boca Raton 431-460
21. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991) 880-885
22. Fromm M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38 (2000) 69-74
23. Spahn-Langguth H., Baktir G., Radschuweit A., Okyar A., Terhaag B., Ader P., et al. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36 (1998) 16-24
24. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.-L., Turgeon D.K., Schmiedlin-Ren P., et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62 (1997) 248-260
25. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.-P., Von Richter O., Zundler J., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104 (1999) 147-153
26. Huisman M.T., Smit J.W., Crommentuyn K.M.L., Zelcer N., Wiltshire H.R., Beijnen J.H., et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16 (2002) 2295-2301
27. Merino G., Álvarez A.I., Pulido M.M., Molina A.J., Schinkel A.H., and Prieto J.G. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab. Dispos. 34 (2006) 690-695
28. Polli J.W., Baughman T.M., Humphreys J.E., Jordan K.H., Mote A.L., Webster L.O., et al. The systemic exposure of an N-methyl-d-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. Drug Metab. Dispos. 32 (2004) 722-726
29. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H.M., et al. Role of breast cancer resistance protein in the bioavailability and foetal penetration of topotecan. J. Natl. Cancer Inst. 92 (2000) 1651-1656
30. Allen J.D., Brinkhuis R.F., Wijnholds J., and Schinkel A.H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59 (1999) 4237-4241
31. Kruijtzer C.M.F., Beijnen J.H., Rosing H., Ten Bokkel Huinink W.W., Schot M., Jewell R.C., et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20 (2002) 2943-2950
32. Walle U.K., and Walle T. Transport of the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) across the human intestinal Caco-2 cell monolayer: role of efflux pumps. Carcinogenesis 20 (1999) 2153-2157
33. Schutte M.E., Van de Sandt J.J.M., Alink G.M., and Groten J.P. Rietjens IMCM. Myricetin stimulates the absorption of the pro-carcinogen PhIP. Cancer Lett. 231 (2006) 36-42
34. Dietrich C.G., De Waart D.R., Ottenhoff R., Schoots I.G., and Oude Elferink R.P.J. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol. Pharmacol. 59 (2001) 974-980
35. Vlaming M.L.H., Mohrmann K., Wagenaar E., De Waart D.R., Oude Elferink R.P.J., Lagas J.S., et al. Carcinogen and anti-cancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J. Pharmacol. Exp. Ther. 318 (2006) 319-327
36. Van Herwaarden A.E., Jonker J.W., Wagenaar E., Brinkhuis R.F., Schellens J.H.M., Beijnen J.H., et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63 (2003) 6447-6452
37. Buesen R., Mock M., Nau H., Seidel A., Jacob J., and Lampen A. Human intestinal Caco-2 cells display active transport of benzo[a]pyrene metabolites. Chem. Biol. Interact. 142 (2003) 201-221
38. Ebert B., Seidel A., and Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26 (2005) 1754-1763
39. Walle U.K., French K.L., Walgren R.A., and Walle T. Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2. Res. Commun. Mol. Pathol. Pharmacol. 103 (1999) 45-56
40. Sesink A.L.A., Arts I.C.W., De Boer V.C.J., Breedveld P., Schellens J.H.M., Hollman P.C.H., et al. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol. 67 (2005) 1999-2006
41. Wang Y., Cao J., and Zeng S.J. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J. Pharm. Pharmacol. 57 (2005) 751-758
42. Vaidyanathan J.B., and Walle T. Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm. Res. 18 (2001) 1420-1425
43. Kuppens I.E.L.M., Breedveld P., Beijnen J.H., and Schellens J.H.M. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest. 23 (2005) 443-464
44. Gottesmann M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 (1993) 385-427
45. König J., Nies A.T., Cui Y., Leier I., and Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461 (1999) 377-394
46. Evers R., De Haas M., Sparidans R., Beijnen J., Wielinga P.R., Lankelma J., et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 83 (2000) 375-383
47. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P., and Deeley R.G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54 (1994) 357-361
48. Leslie E.M., Deeley R.G., and Cole S.P.C. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167 (2001) 3-23
49. Fojo T., and Bates S. Strategies for reversing drug resistance. Oncogene 22 (2003) 7512-7523
50. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455 (1976) 152-162
51. Leonard G.D., Fojo T., and Bates S.E. The role of ABC transporters in clinical practice. Oncologist 8 (2003) 411-424
52. Haimeur A., Conseil G., Deeley R.G., and Cole S.P.C. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 5 (2004) 21-53
53. Sparreboom A., Danesi R., Ando Y., Chan J., and Figg W.D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. 6 (2003) 71-84
54. Cnubben N.H.P., Rommens A.J.M., Oudshoorn M.J., and Van Bladeren P.J. Glutathione-dependent biotransformation of the alkylating drug thiotepa and transport of its metabolite monoglutathionylthiotepa in human MCF-7 breast cancer cells. Cancer Res. 58 (1998) 4616-4623
55. Grzywacz M.J., Yang J.-M., and Hait W.N. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res. 63 (2003) 2492-2498
56. Olson D.P., Scadden D.T., D'Aquila R.T., and De Pasquale M.P. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 16 (2002) 1743-1747
57. Williams G.C., Liu A., Knipp G., and Sinko P.J. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother. 46 (2002) 3456-3462
58. Han B., and Zhang J.T. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr. Med. Chem. Anticancer Agents 4 (2004) 31-42
59. Plasschaert S.L.A., Van der Kolk D.M., De Bont E.S.J.M., Vellenga E., Kamps W.A., and De Vries E.G.E. Breast cancer resistance protein (BCRP) in acute leukemia. Leuk. Lymphoma 45 (2004) 649-654
60. Mao Q., and Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7 (2005) E118-EE33
61. Avendano C., and Menendez J.C. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Med. Chem. 9 (2002) 159-193
62. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., Beketic-Oreskovic L., and Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40 (1997) S13-SS9
63. Sugimoto Y., Tsukahara S., Ishikawa E., and Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci. 96 (2005) 457-465
64. Di Pietro A., Conseil G., Perez-Victoria J.M., Dayan G., Baubichon-Cortay H., Trompier D., et al. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell. Mol. Life Sci. 59 (2002) 307-322
65. Borst P., and Oude Elferink R. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71 (2002) 537-592
66. Tan B., Piwnica-Worms D., and Ratner L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12 (2000) 450-458
67. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.-M., Barron D., and Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. USA 95 (1998) 9831-9836
68. Leslie E.M., Mao Q., Oleschuk C.J., Deeley R.G., and Cole S.P.C. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol. Pharmacol. 59 (2001) 1171-1180
69. Trompier D., Baubichon-Cortay H., Chang X.-B., Maitrejean M., Barron D., Riordon J.R., et al. Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell. Mol. Life Sci. 60 (2003) 2164-2177
70. Aherne S.A., and O'Brien N.M. Dietary flavonols: chemistry, food content, and metabolism. Nutrition 18 (2002) 75-81
71. Ader P., Wessmann A., and Wolffram S. Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic. Biol. Med. 28 (2000) 1056-1067
72. Day A.J., Bao Y., Morgan M.R.A., and Williamson G. Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic. Biol. Med. 29 (2000) 1234-1243
73. Day A.J., Mellon F., Barron D., Sarrazin G., Morgan M.R.A., and Williamson G. Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic. Res. 35 (2001) 941-952
74. Mullen W., Graf B.A., Caldwell S.T., Hartley R.C., Duthie G.G., Edwards C.A., et al. Determination of flavonol metabolites in plasma and tissues of rats by HPLC-radiocounting and tandem mass spectrometry following oral ingestion of [2-(14)C]quercetin-4′-glucoside. J. Agric. Food Chem. 50 (2002) 6902-6909
75. Spencer J.P.E., Abd-el-Mohsen M.M., and Rice-Evans C. Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch. Biochem. Biophys. 423 (2004) 148-161
76. Havsteen B.H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96 (2002) 67-202
77. Rice-Evans C. Flavonoid antioxidants. Curr. Med. Chem. 8 (2001) 797-807
78. Williams R.J., Spencer J.P.E., and Rice-Evans C. Flavonoids: antioxidants or signalling molecules?. Free Radic. Biol. Med. 36 (2004) 838-849
79. Le Marchand L. Cancer preventive effects of flavonoids-a review. Biomed. Pharmacother. 56 (2002) 296-301
80. Lopez-Lazaro M. Flavonoids as anticancer agents: structure-activity relationship study. Curr. Med. Chem. Anticancer Agents 2 (2002) 691-714
81. Yang C.S., Landau J.M., Huang M.-T., and Newmark H.L. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr. 21 (2001) 381-406
82. Kris-Etherton P.M., and Keen C.L. Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Curr. Opin. Lipidol. 13 (2002) 41-49
83. Ross J.A., and Kasum C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr. 22 (2002) 19-34
84. Steinberg F.M., Bearden M.M., and Keen C.L. Cocoa and chocolate flavonoids: implications for cardiovascular health. J. Am. Diet. Assoc. 103 (2003) 215-223
85. Inanami O., Watanabe Y., Syuto B., Nakano M., Tsuji M., and Kuwabara M. Oral administration of (-)catechin protects against ischemia-reperfusion-induced neuronal death in the gerbil. Free Radic. Res. 29 (1998) 359-365
86. Joseph J.A., Shukitt-Hale B., Denisova N.A., Bielinski D., Martin A., McEwen J.J., et al. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J. Neurosci. 19 (1999) 8114-8121
87. Joseph J.A., Shukitt-Hale B., Denisova N.A., Prior R.L., Cao G., Martin A., et al. Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J. Neurosci. 18 (1998) 8047-8055
88. Potter S.M., Baum J.A., Teng H., Stillman R.J., Shay N.F., and Erdman J.W.J. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 68 (1998) 1375S-1379S
89. Boumendjel A., Baubichon-Cortay H., Trompier D., Perrotton T., and Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. 25 (2005) 453-472
90. Zhang S., Wang X., Sagawa K., and Morris M.E. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab. Dispos. 33 (2005) 341-348
91. Zhang S., Yang X., and Morris M.E. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res. 21 (2004) 1263-1273
92. Zhang S., Yang X., and Morris M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65 (2004) 1208-1216
93. Hong J., Lambert J.D., Lee S.-H., Sinko P.J., and Yang C.S. Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem. Biophys. Res. Commun. 310 (2003) 222-227
94. Van Zanden J.J., De Mul A., Wortelboer H.M., Usta M., Van Bladeren P.J., Rietjens I.M.C.M., et al. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem. Pharmacol. 69 (2005) 1657-1665
95. Van Zanden J.J., Wortelboer H.M., Bijlsma S., Punt A., Usta M., Van Bladeren P.J., et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol. 69 (2005) 699-708
96. Ikegawa T., Ushigome F., Koyabu N., Morimoto S., Shoyama Y., Naito M., et al. Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett. 160 (2000) 21-28
97. Takanaga H., Ohnishi A., Yamada S., Matsuo H., Morimoto S., Shoyama Y., et al. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J. Pharmacol. Exp. Ther. 293 (2000) 230-236
98. Jodoin J., Demeule M., and Béliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta 1542 (2002) 149-159
99. Scambia G., Ranelletti F.O., Panici P.B., De Vincenzo R., Bonanno G., Ferrandina G., et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 34 (1994) 459-464
100. Tseng E., Liang W., Wallen C., and Morris M.E. Effect of flavonoids of P-glycoprotein-mediated transport in a human breast cancer cell line (2001), AAPS National Meetings, Denver, USA
101. Castro A.F., and Altenberg G.A. Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem. Pharmacol. 53 (1997) 89-93
102. Eagling V.A., Profit L., and Back D.J. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48 (1999) 543-552
103. Sergent T., Garsou S., Schaut A., De Saeger S., Pussemier L., Van Peteghem C., et al. Differential modulation of ochratoxin A absorption across Caco-2 cells by dietary polyphenols, used at realistic intestinal concentrations. Toxicol. Lett. 159 (2005) 60-70
104. Berger V., Gabriel A.-F., Sergent T., Trouet A., Larondelle Y., and Schneider Y.-J. Interaction of ochratoxin A with human intestinal Caco-2 cells: possible implication of a multidrug resistance-associated protein (MRP2). Toxicol. Lett. 140-141 (2003) 465-476
105. Zhang S., and Morris M.E. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm. Res. 20 (2003) 1184-1191
106. Deferme S., and Augustijns P. The effect of food components on the absorption of P-gp substrates: a review. J. Pharm. Pharmacol. 55 (2003) 153-162
107. Zhou S., Lim L.Y., and Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab. Rev. 36 (2004) 57-104
108. Choi J.-S., Jo B.-W., and Kim Y.-C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm. 57 (2004) 313-318
109. Choi J.-S., Choi H.-K., and Shin S.-C. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm. 275 (2004) 165-170
110. Imai Y., Tsukahara S., Asada S., and Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 64 12 (2004) 4346-4352
111. Romiti N., Tramonti G., Donati A., and Chieli E. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci. 76 (2004) 293-302
112. Choi J.-S., and Han H.-K. Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats. Int. J. Pharm. 305 (2005) 122-128
113. Choi J.-S., and Han H.-K. Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol. Res. 52 (2005) 386-391
114. Edwards D.J., Fitzsimmons M.E., Schuetz E.G., Yasuda K., Ducharme M.P., Warbasse L.H., et al. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin. Pharmacol. Ther. 65 (1999) 237-244
115. Flanagan D. Understanding the grapefruit-drug interaction. Gen. Dent. 53 (2005) 282-285
116. Tian R., Koyabu N., Takanaga H., Matsuo H., Ohtani H., and Sawada Y. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm. Res. 19 (2002) 802-809
117. Spahn-Langguth H., and Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12 (2001) 361-367
118. Wagner D., Spahn-Langguth H., Hanafy A., Koggel A., and Langguth P. Intestinal drug efflux: formulation and food effects. Adv. Drug Deliv. Rev. 50 (2001) S13-S31
119. Di Marco M.P., Edwards D.J., Wainer I.W., and Ducharme M.P. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci. 71 (2002) 1149-1160
120. Becquemont L., Verstuyft C., Kerb R., Brinkmann U., Lebot M., Jaillon P., et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70 (2001) 311-316
121. Soldner A., Christians U., Susanto M., Wacher V.J., Silverman J.A., and Benet L.Z. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm. Res. 16 (1999) 478-485
122. Lo Y.L., and Huang J.D. Comparison of effects of natural or artificial rodent diet on etoposide absorption in rats. In Vivo 13 (1999) 51-55
123. Scalbert A., and Williamson G. Dietary intake and bioavailability of polyphenols. J. Nutr. 130 (2000) 2073S-2085S
124. Leslie E.M., Deeley R.G., and Cole S.P.C. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 (2005) 216-237
125. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 (2000) 1295-1302
126. Ritter C.A., Jedlitschky G., Meyer Z.U., Schwabedissen H., Grube M., Köck K., and Kroemer H.K. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev. 37 (2005) 253-278
127. Zelcer N., Reid G., Wielinga P., Kuil A., Van der Heijden I., Schuetz J.D., et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J. 371 (2003) 361-367
128. Wielinga P., Hooijberg J.H., Gunnarsdottir S., Kathmann I., Reid G., Zelcer N., et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 65 (2005) 4425-4430
129. Krishnamurthy P., and Schuetz J.D. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 381-410
130. Sarkadi B., Özvegy-Laczka C., Német K., and Váradi A. ABCG2-a transporter for all seasons. FEBS Lett. 567 (2004) 116-120
131. Staud F., and Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int. J. Biochem. Cell Biol. 37 (2005) 720-725
132. Van Herwaarden A.E., and Schinkel A.H. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol. Sci. 27 (2006) 10-16
133. Chung S.Y., Sung M.K., Kim N.H., Jang J.O., Go E.J., and Lee H.J. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch. Pharm. Res. 28 (2005) 823-828
134. Kitagawa S., Nabekura T., and Kamiyama S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol. 56 (2004) 1001-1005
135. Kitagawa S., Nabekura T., Takahashi T., Nakamura Y., Sakamoto H., Tano H., et al. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol. Pharm. Bull. 28 (2005) 2274-2278
136. Ofer M., Wolffram S., Koggel A., Spahn-Langguth H., and Langguth P. Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT?. Eur. J. Pharm. Sci. 25 (2005) 263-271
137. Walgren R.A., Karnaky K.J.J., Lindenmayer G.E., and Walle T. Efflux of dietary flavonoid quercetin-4′-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J. Pharmacol. Exp. Ther. 294 (2000) 830-836
138. Zhang S., and Morris M.E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther. 304 (2003) 1258-1267
139. Lania-Pietrzak B., Michalak K., Hendrich A.B., Mosiadz D., Grynkiewicz G., Motohashi N., et al. Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids. Life Sci. 77 (2005) 1879-1891
140. Nguyen H., Zhang S., and Morris M.E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci. 92 (2003) 250-257
141. Wu C.-P., Calcagno A.M., Hladky S.B., Ambudkar S.V., and Barrand M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 272 (2005) 4725-4740
142. Ahmed-Belkacem A., Pozza A., Muñoz-Martinez F., Bates S.E., Castanys S., Gamarro F., et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res. 65 (2005) 4852-4860
143. Cooray H.C., Janvilisri T., Van Veen H.W., Hladky B., and Barrand M.A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun. 317 (2004) 269-275
144. Yoshikawa M., Ikegami Y., Sano K., Yoshida H., Mitomo H., Sawada S., et al. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J. Exp. Ther. Oncol. 4 (2004) 25-35
145. Takanaga H., Ohnishi A., Matsuo H., and Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol. Pharm. Bull. 21 (1998) 1062-1066
146. Versantvoort C.H.M., Broxterman H.J., Lankelma J., Feller N., and Pinedo H.M. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 48 (1994) 1129-1136
147. Limtrakul P., Khantamat O., and Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J. Chemother. 17 (2005) 86-95
148. Chieli E., Romiti N., Cervelli F., and Tongiani R. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci. 57 (1995) 1741-1751
149. Rodriguez-Proteau R., Mata J.E., Miranda C.L., Fan Y., Brown J.J., and Buhler D.R. Plant polyphenols and multidrug resistance: effects of dietary flavonoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models. Xenobiotica 36 (2006) 41-58
150. Pinto M., Robine-Leon S., Appay M.-D., Kedinger M., Triadou N., Dussaulx E., et al. Enterocyte-like differentiation and polarisation of the human colon carcinoma cell line Caco-2. Biol. Cell. 47 (1983) 323-330
151. Karlsson J., and Artursson P. A method for the determination of cellular permeability coefficients and aquous boundary layer thickness in monolayers of intestinal epithelial (Caco-2) cells grown in permeable filter chambers. Int. J. Pharmaceutics 71 (1991) 55-64